Prenetics Group Limited (PRE): Price and Financial Metrics
PRE Price/Volume Stats
|Current price||$0.45||52-week high||$3.85|
|Prev. close||$0.49||52-week low||$0.42|
|Day high||$0.46||Avg. volume||399,245|
|50-day MA||$0.58||Dividend yield||N/A|
|200-day MA||$0.99||Market Cap||61.64M|
PRE Stock Price Chart Interactive Chart >
Prenetics Group Limited (PRE) Company Bio
Prenetics Group Limited operates as a diagnostics and genetic testing company worldwide. It develops consumer genetic testing and early colorectal cancer screening products; and provides COVID-19 testing, rapid point of care and at-home diagnostic testing, and medical genetic testing products. The company's products include CircleDNA, a consumer genetic testing offering that uses whole exome sequencing; Project Screen, a COVID-19 test; and Circle HealthPod, a molecular testing product for COVID-19. It is also developing ColoClear, a non-invasive stool-based FIT-DNA test for colorectal cancer screening; Circle SnapShot, an at-home blood test with a user-friendly blood sample collection and result delivery system; Circle Medical, a test to identify causal genetic mutations for patients; and Circle One and F1x/Fem, a DNA profile and questionnaire based personalized nutrition solution. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
PRE Latest News Stream
|Loading, please wait...|
PRE Latest Social Stream
View Full PRE Social Stream
Latest PRE News From Around the Web
Below are the latest news stories about PRENETICS GLOBAL LTD that investors may wish to consider to help them evaluate PRE as an investment opportunity.
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.
A World's First: The Miss Hong Kong Pageant 2023 Unveiled Contestants' CircleDNA Results Live on Television
In a move that had never been seen before, marrying beauty with science, the Miss Hong Kong Pageant 2023, which just aired on TVB, had set out to revolutionize the industry by partnering with CircleDNA to unveil contestants' DNA results live on television. This ground-breaking initiative marked the first time in the history of beauty pageants worldwide that such a reveal had taken place.
By Daniella Parra Prenetics Global Limited (NASDAQ: PRE) and Prof. Dennis Lo, the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong have formed a joint venture named Insighta, aiming to revolutionize multi-cancer early detection screening. The transaction, valued at $200 million, will leverage Prof. Lo’s “FRAGMA” technology for cancer screening, […]
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening
Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening (Prof. Dennis Lo and Danny Yeung at Signing Ceremony) (Prof. Dennis Lo and Danny Yeung at Signing Ceremony) - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostic
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent business updates.
PRE Price Returns